# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Leland Gershell maintains Soleno Therapeutics (NASDAQ:SLNO) with a Outperform and raises the price targe...
Soleno Therapeutics (NASDAQ:SLNO) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $...
Cantor Fitzgerald analyst Kristen Kluska reiterates Soleno Therapeutics (NASDAQ:SLNO) with a Overweight and maintains $67 pr...
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therape...
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therape...
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance r...
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therape...